NAVB

Navidea Biopharmaceuticals, Inc. (NAVB) | Rumor.io

Navidea Biopharmaceuticals

NAVB

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)14.6K

Net income (annual)-15.2M

Social

What share of all stock conversation is about NAVB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 21

Navidea Biopharmaceuticals, Inc. (NAVB) is planning a reverse stock split to reduce the number of outstanding shares from 100,000,000 to 2,000.
The company's goal is to avoid reporting requirements with the SEC, as it would have to file financials with the commission due to exceeding the 2,000 investor limit and $10 million in combined assets.
The reverse split may also allow the company to "go further off grid" by potentially locking in a high stock price, although this is speculative.

Generated by AI

Sentiment

Of the messages about NAVB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	50% +3.85
Bearish	—	—	—	50% -3.85

Bullish· Oct 6

The company has a 1-2B pipeline in the immunotherapy/rheumatoid space, which could lead to acquisition or significant growth in 2024Q1.
Insiders have purchased millions of shares at the end of July, indicating confidence in the company's future.
The company has ongoing licensing partnerships and non-dilutive capital raise options, which could help meet its business goals and potentially drive the stock price higher.

Bearish· Oct 6

The company has made a recent announcement that has strung out investors, and a 14A filing has been made to inflict more pain on investors.
The stock has been trading at a significantly lower price than reflected in Yahoo Finance, raising questions about its accuracy.
The company's recent actions, including a potential dilution of shares and a long-term wish list, may indicate a lack of concern for shareholders and a focus on short-term gains.

Generated by AI

Topics

Of the messages about NAVB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Jun 16

Navidea Biopharmaceuticals secured $7.5m cash payment from Cardinal Health, waiving its right to a milestone payment.
The company's stock price surged by 33.29% on the news, and the stock was halted due to pending news.
Navidea Biopharmaceuticals received new coverage from analysts, and the company's shares are up 12.09% after hours.

Technical Analysis· May 22

$NAVB is at a critical level, with a potential short opportunity and a risk of a significant price drop.
The stock has formed a double bottom pattern, indicating a potential reversal, and is showing signs of a possible uptrend.
$NAVB has a strong resistance level at $2.75, which has been tested and bounced off, and may be a key area to watch for a potential reversal.

Generated by AI

Community

Of the messages about NAVB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	37.84%
Newcomers	—	—	—	62.16%

Regulars· Jun 16

Navidea Biopharmaceuticals, Inc. (NAVB) has seen significant price swings, with a 80.98% increase in one instance, and a 13.20% decrease in another.
The company's stock has experienced heavy volume, with all indicators pointing to a potential "pop" in one post, and a relatively large volume trade on a medium float stock in another.
Navidea Biopharmaceuticals has received a $7.5m cash payment and waived its right to receive any Milestone Payment from Cardinal Health, leading to a 33.29% increase in the stock's price on the same day.

Newcomers· Jun 22

The stock has seen a significant price increase, up 21.88%, due to increased investor interest driven by a potential partnership with a UAE-based e-script medicine management company.
The stock has been heavily shorted, and some users believe it has the potential to reach $1 in the next 24 hours, with one user noting that it already reached $1 premarket.
The stock is seeing increased volume, with some users predicting afternoon action if the volume continues, and others noting that the only way to get shares is to buy at the current high ask price.

Generated by AI

Also Discussed

Investors talking about NAVB also mention

#	Name	Attention
1	HZNP - Horizon Therapeutics Public Limited Company	——
2	Xtant Medical Holdings Inc.XTNT	0%0
3	Exelixis Inc.EXEL	0%-0.03
4	Amarin Corporation plc ADRAMRN	0%+0
5	Catalyst Pharmaceuticals Inc.CPRX	0%new
6	DRRX - DURECT Corporation	——
7	Celldex Therapeutics IncCLDX	0%+0
8	BCEI - Civitas Resources, Inc.	——
9	BLPH - Bellerophon Therapeutics, Inc.	——
10	Corgi All Commodities 2x Daily ETFXCOM	0%0

Navidea Biopharmaceuticals, Inc.

Healthcare
Biotechnology

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing precision immunodiagnostic agents and immunotherapeutics. Its primary function is to enhance the ability to accurately identify and treat diseases, specifically through its proprietary technology based on the Manocept platform. This platform is designed to target and illuminate cells with high-level receptor activity, making it particularly significant in the fields of oncology, rheumatology, and neurology. Notable developments include its diagnostic products which address unmet medical needs by improving diagnostic accuracy and patient outcomes. Navidea Biopharmaceuticals is strategically positioned within the biotechnology sector, emphasizing innovation in detecting and managing conditions such as rheumatoid arthritis and various types of cancer. By leveraging its unique technological advancements, the company plays a crucial role in enhancing diagnostic imaging and therapeutic interventions, contributing to the overall progress and precision of medical treatments available in the market.

Website

Location

4995 Bradenton Avenue

Dublin, OH, 43017-3552

United States

Social

What share of all stock conversation is about NAVB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 21

Navidea Biopharmaceuticals, Inc. (NAVB) is planning a reverse stock split to reduce the number of outstanding shares from 100,000,000 to 2,000.
The company's goal is to avoid reporting requirements with the SEC, as it would have to file financials with the commission due to exceeding the 2,000 investor limit and $10 million in combined assets.
The reverse split may also allow the company to "go further off grid" by potentially locking in a high stock price, although this is speculative.

Generated by AI

Sentiment

Of the messages about NAVB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	50% +3.85
Bearish	—	—	—	50% -3.85

Bullish· Oct 6

The company has a 1-2B pipeline in the immunotherapy/rheumatoid space, which could lead to acquisition or significant growth in 2024Q1.
Insiders have purchased millions of shares at the end of July, indicating confidence in the company's future.
The company has ongoing licensing partnerships and non-dilutive capital raise options, which could help meet its business goals and potentially drive the stock price higher.

Bearish· Oct 6

The company has made a recent announcement that has strung out investors, and a 14A filing has been made to inflict more pain on investors.
The stock has been trading at a significantly lower price than reflected in Yahoo Finance, raising questions about its accuracy.
The company's recent actions, including a potential dilution of shares and a long-term wish list, may indicate a lack of concern for shareholders and a focus on short-term gains.

Generated by AI

Topics

Of the messages about NAVB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Jun 16

Navidea Biopharmaceuticals secured $7.5m cash payment from Cardinal Health, waiving its right to a milestone payment.
The company's stock price surged by 33.29% on the news, and the stock was halted due to pending news.
Navidea Biopharmaceuticals received new coverage from analysts, and the company's shares are up 12.09% after hours.

Technical Analysis· May 22

$NAVB is at a critical level, with a potential short opportunity and a risk of a significant price drop.
The stock has formed a double bottom pattern, indicating a potential reversal, and is showing signs of a possible uptrend.
$NAVB has a strong resistance level at $2.75, which has been tested and bounced off, and may be a key area to watch for a potential reversal.

Generated by AI

Community

Of the messages about NAVB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	37.84%
Newcomers	—	—	—	62.16%

Regulars· Jun 16

Navidea Biopharmaceuticals, Inc. (NAVB) has seen significant price swings, with a 80.98% increase in one instance, and a 13.20% decrease in another.
The company's stock has experienced heavy volume, with all indicators pointing to a potential "pop" in one post, and a relatively large volume trade on a medium float stock in another.
Navidea Biopharmaceuticals has received a $7.5m cash payment and waived its right to receive any Milestone Payment from Cardinal Health, leading to a 33.29% increase in the stock's price on the same day.

Newcomers· Jun 22

The stock has seen a significant price increase, up 21.88%, due to increased investor interest driven by a potential partnership with a UAE-based e-script medicine management company.
The stock has been heavily shorted, and some users believe it has the potential to reach $1 in the next 24 hours, with one user noting that it already reached $1 premarket.
The stock is seeing increased volume, with some users predicting afternoon action if the volume continues, and others noting that the only way to get shares is to buy at the current high ask price.

Generated by AI

Navidea Biopharmaceuticals

Social

Jun 21

Sentiment

Bullish· Oct 6

Bearish· Oct 6

Topics

Announcements· Jun 16

Technical Analysis· May 22

Community

Regulars· Jun 16

Newcomers· Jun 22

Also Discussed

Navidea Biopharmaceuticals, Inc.

Company Information

Location

Also Discussed

Social

Jun 21

Sentiment

Bullish· Oct 6

Bearish· Oct 6

Topics

Announcements· Jun 16

Technical Analysis· May 22

Community

Regulars· Jun 16

Newcomers· Jun 22